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Abstract 34 
Antibiotics are among the most important interventions in healthcare. Resistance of 35 
bacteria to antibiotics threatens their effectiveness. Systematic reviews of antibiotic 36 
treatments often do not address resistance to antibiotics even when data are available in 37 
the original studies. This creates a skewed view, which emphasizes short term efficacy 38 
and ignores the long term consequences to the patient and other people.  39 
We offer a framework for addressing antibiotic resistance in systematic reviews. We 40 
suggest that the data on background resistance in the original trials should be reported 41 
and taken into account when interpreting results. Data on emergence of resistance 42 
(whether in the body reservoirs or in the bacteria causing infection) are important 43 
outcomes. Emergence of resistance should be taken into account when interpreting the 44 
evidence on antibiotic treatment in randomized controlled trials or systematic reviews. 45 
 46 
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Introduction 48 
Antibiotics are one of the most important interventions in healthcare, 49 
substantially reducing mortality and morbidity in severe bacterial infections. Many 50 
medical procedures could not be safely performed without antibiotics. Resistance of 51 
microorganisms to antibiotics threatens to undo these gains, and there is convincing 52 
evidence that consumption of antibiotic drugs induces resistance.1 53 
Guidelines and clinical decisions are frequently based on systematic reviews. 54 
Between June 2014 and June 2015 approximately 140 systematic reviews on antibiotic 55 
treatment were published. However systematic reviews on antibiotic treatment often 56 
did not address resistance to antibiotics even when data were available in the original 57 
trials.2 The major cost of antibiotic treatment is probably the harm to future patients 58 
from emergence of resistance.3-5 If emerging resistance is ignored in systematic 59 
reviews, readers are presented with a skewed view, stressing short-term efficacy and 60 
ignoring the long term consequences to the patient and other people.  61 
Fighting the rise in antibiotic resistance is a global concern. The WHO has 62 
recently endorsed a global action plan on antimicrobial resistance with “…five strategic 63 
objectives: (i) to improve awareness and understanding of antimicrobial resistance; (ii) 64 
to strengthen knowledge through surveillance and research; (iii) to reduce the incidence 65 
of infection; (iv) to optimize the use of antimicrobial agents; and (v) to ensure 66 
sustainable investment in countering antimicrobial resistance.”6 Considering resistance 67 
to antimicrobials in systematic reviews and in the original trials can address at least 68 
three of these goals. Authors of systematic reviews can join this effort. This article 69 
outlines a framework for addressing resistance to antibiotics in systematic reviews. 70 
Which systematic reviews?  71 
The types of antibiotic interventions where resistance should be considered 72 
are detailed in Figure 1. We have selected these interventions (and comparisons) based 73 
on the potential divergent influence of the two arms on promoting resistance.   74 
There are three main steps in the expansion of resistance that might be 75 
influenced by antibiotic interventions: induction of resistant bacteria in the patient 76 
treated with antibiotic drugs; selection of resistant strains in the individual treated; and 77 
spread of the resistant bacteria to other people and the surroundings. Because of 78 
randomized controlled trials’ short timescale only induction and selection of resistant 79 
 
 
strains are relevant for most systematic reviews on antibiotic treatment. But for some 80 
interventions both induction and selection of resistance and also spread can be 81 
addressed (e.g. large scale use of antibiotics in a community.7 82 
Baseline resistance and its influence on outcomes 83 
To be useful to policy development, systematic reviews of antibiotic 84 
interventions must consider the influence of antibiotic resistance on the wider 85 
applicability of the review results. Development of resistance over time might lower 86 
the efficacy of drugs tested in old trials. New antibiotics will appear superior to old ones 87 
if only evaluated in areas with resistance to the old comparator drug, where the (old) 88 
comparator drug is failing. Comparison of a new, broad spectrum antibiotic drug with 89 
an old drug for which resistance is more abundant adds little to our understanding if the 90 
efficacy of the drugs is not compared in the sub-group of patients with susceptible 91 
pathogens.  92 
A systematic review may include studies that were done a long time ago; or 93 
done only in certain regions, with local profiles of resistance. Reviewers need to take 94 
these differences into account when interpreting their results and discussing their 95 
applicability. They should refer to current patterns of resistance and their distribution. 96 
In Figure 2 we make recommendations regarding the data that should be sought and 97 
extracted from primary studies into systematic reviews and considered in their 98 
interpretation. If data are missing, systematic description of the absence of important 99 
information in the primary studies will encourage those embarking on new primary 100 
studies to consider collecting important information relevant to resistance. 101 
Resistance as an outcome 102 
During antibiotic treatment bacteria resistant to the administered drug have 103 
an advantage and might grow in the main non-sterile reservoirs of the body, such as the 104 
bowel, naso-pharynx, and skin. Documentation of such changes demands surveillance 105 
cultures during and after the trial. This is not done in many trials, as it requires 106 
resources, and is an additional burden imposed onto the participants. However in some 107 
trials surveillance cultures were done;2 and the results can be incorporated in systematic 108 
reviews. 109 
Data on super-imposed bacterial infections by pathogens resistant to the study 110 
antibiotic during or shortly after treatment should be collected as outcomes. Even if 111 
 
 
susceptibilities to antibiotics were not reported, bacterial infections during antibiotic 112 
treatment suggest resistance to the antibiotic drug. Emergence of resistance in the index 113 
pathogen (initially susceptible) during treatment is rare in acute infections but important 114 
when it occurs. However, in some cases treatment is given for chronic infection, where 115 
eradication of the organism is unlikely, (for example anti-pseudomonal antibiotics for 116 
lung infection in cystic fibrosis). It is particularly important to report resistance data in 117 
systematic reviews in these conditions, as treatment is often lifelong and selection of 118 
resistant organisms is commonplace.8 119 
In studies in which a whole population or group of people were exposed to 120 
an antibiotic intervention (for example azithromycin for trachoma7 or decontamination 121 
of the oropharynx and intestinal tract in intensive care units,9 the changes in resistance 122 
over time in the population are important and should be collected. Figure 3 details the 123 
data that should ideally be gathered on resistance as outcome in trials of antibiotic 124 
interventions.  125 
Conclusions 126 
Not all trials report data relevant to antibiotic resistance. Where trials report 127 
resistance these data should be extracted, analysed and used in the interpretation of 128 
systematic reviews. Where data on antibiotic resistance are not available, the 129 
implications of resistance should be considered in the discussion section. Systematic 130 
reviews can point to areas where crucial data on resistance are missing from the original 131 
studies, setting a research agenda. 132 
We offer a framework for data collection and discussion. The same 133 
considerations apply to systematic reviews on anti-viral and anti-fungal agents. 134 
We aim to draw on this framework in the development of Cochrane protocols 135 
and reviews. We hope that the use of this framework in systematic reviews will 136 
encourage researchers to include reference to resistance in the design of their trials and 137 
in their reports. We also hope that the readers of these systematic reviews will look for 138 
data on resistance and incorporate them in their decisions on treatment and policy. 139 
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Figure 1: Systematic reviews that should address resistance to antibiotics 174 
Comparisons between: 
 An antibiotic drug versus no treatment, placebo, delayed treatment or a non-
antibiotic intervention. 
 Antibiotic drugs or combinations of antibiotics. 
 Different durations of antibiotic treatment. 
 Different dosing of antibiotic drugs. 
 Antibiotic de-escalation/ escalation strategies. 
 Antibiotic prophylaxis. 
 Mass programmes of antibiotic drug administration. 
 Interventions to improve antibiotic prescribing. 
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Figure 2: Contextual data about baseline antibiotic resistance to be 177 
considered in systematic reviews 178 
Data to be collected and reported for each trial included in the systematic review: 
 Percentage of resistance to the trial drugs in the trial participants. 
 Percentage of resistance to the trial drugs at the time and location/s the 
trials were conducted; and in the populations of interest. 
 Alongside the main comparisons of the outcomes of interest in all 
randomized patients by intention to treat, outcomes should be compared in 
the sub-groups of patients with isolates susceptible to the antibiotic given in 
the specific arm; resistant to this antibiotic; and in patients with sterile 
cultures. Especially in non-inferiority trials, outcomes should be compared 
in these sub-groups in a per-protocol analysis as well. 
 
Interpretation of results: 
 Discuss the results of the systematic review in populations of interest in the 
context of the present distribution of pathogens and their susceptibility to 
antibiotics compared to the time and location of the trials included in the 
review. 
 Discuss the efficacy of the drugs in the intent to treat analysis; but also in 
context of the efficacy in the sub-group of patients with susceptible isolates. 
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Figure 3: Antibiotic resistance as an outcome to be collected in systematic 181 
reviews of antibiotic interventions 182 
Data to be collected: 
 Isolation of resistant bacteria from surveillance cultures of body reservoirs 
during and after antibiotic treatment. 
 Super-infections with resistant pathogens during and after antibiotic 
treatment. 
 Any bacterial super-infection during antibiotic treatment. 
 Development of resistance in the index pathogen. 
 In relevant studies, change in resistance in the population. 
Interpretation of results: 
 If resistance-related outcomes are different between the arms of the trial, 
discuss the implications for policy and practice. 
 If no data are available, discuss what is known about resistance to the drugs 
of interest from other sources, and how it can influence policy and practice. 
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